Table 2 Frequency of cardiovascular toxicities by treatment received
Anthracycline only | VEGF inhibitor only | Anthracycline and VEGF inhibitor (N = 74) | |||||||
|---|---|---|---|---|---|---|---|---|---|
(N = 891) | (N = 200) | ||||||||
N | (%) | N | (%) | aHR (95% CI) | N | (%) | aHR (95% CI) | p* | |
Any Cardiovascular Toxicity | 230 | (25.8) | 38 | (19.0) | 0.72 (0.51–1.01) | 22 | (29.7) | 1.06 (0.70–1.61) | 0.15 |
Hypertension | 172 | (21.0) | 30 | (17.4) | 0.84 (0.57–1.24) | 21 | (30.0) | 1.32 (0.85–2.05) | 0.27 |
Cardiomyopathy/heart failure | 12 | (1.4) | 0 | (0) | - | 0 | (0) | - | * |
Cardiomegaly | 3 | (0.3) | 1 | (0.5) | - | 0 | (0) | - | * |
Pericardial disease | 21 | (2.4) | 2 | (1.0) | - | 0 | (0) | - | * |
Myocardial infarction | 4 | (0.5) | 0 | (0) | - | 0 | (0) | - | * |
Coronary artery disease | 1 | (0.1) | 0 | (0) | - | 0 | (0) | - | * |
Conduction abnormality/dysrhythmia | 47 | (5.3) | 5 | (2.5) | 0.45 (0.18–1.13) | 2 | (2.7) | 0.48 (0.12–1.95) | 0.15 |
Cerebrovascular event | 3 | (0.3) | 1 | (0.5) | - | 0 | (0) | - | * |
Valvular degeneration | 5 | (0.6) | 1 | (0.5) | 0.72 (0.09–5.88) | 2 | (2.8) | 4.47 (0.82–24.43) | 0.17 |
Peripheral vascular disease | 7 | (0.8) | 0 | (0) | - | 0 | (0) | - | * |